Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
about
Management of sexual dysfunction due to antipsychotic drug therapyRisperidone versus other atypical antipsychotics for schizophreniaAmisulpride versus other atypical antipsychotics for schizophreniaManagement of sexual dysfunction due to antipsychotic drug therapyThe use of amisulpride in the treatment of acute psychosisThe effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study.Is the PANSS used correctly? a systematic review.Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Almost all antipsychotics result in weight gain: a meta-analysis.Safety and tolerability of antipsychotics: focus on amisulpride.Weight gain profiles of new anti-psychotics: public health consequences.Risperidone: a review.The relationship between patient satisfaction and treatment outcomes in schizophrenia.Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorderDropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresThe effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study.Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.Quality of life and functioning in first-episode psychosis Chinese patients with different antipsychotic medications.Update on the management of symptoms in schizophrenia: focus on amisulpride.Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.Development of novel amisulpride-loaded solid self-nanoemulsifying tablets: preparation and pharmacokinetic evaluation in rabbits.A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.Prandial effect on the systemic exposure of amisulpride.Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone.
P2860
Q24197558-B77076A4-C9F2-4771-983D-1A33AC34B80BQ24234950-5D8102FC-9817-4A31-A7D8-94AF85D1DF3AQ24240433-9572713D-651A-4E5B-8B5D-32CACEB05C91Q24246362-E91A8919-A796-4FF1-9463-0248F18D8E1DQ24683055-3B66F98E-60EE-497F-8EAF-A00C80832FFBQ24800019-A056F5E2-BA43-4AF7-B81A-8043874D4CC0Q33223628-611FC44B-A1BA-483E-A5F0-B5718C4E38BFQ33235110-A849D6F1-36FC-4140-A5C4-A12C7D3F7DF9Q33609974-F8400294-204F-4115-8890-BC607847D237Q33879147-FFFF1388-1ED5-4D4B-9A43-44535FBAB597Q33964357-DEB997B5-0354-4B80-81B7-6A06ABFC573BQ34037969-5D3A36B7-9B22-4F1F-82D5-A1835544846DQ34640811-0E402353-9FA5-4C4A-9856-DA4DADD63F2BQ34661499-D384BC4D-86EB-4B95-85EC-BFEF2B6D7EBCQ35026487-E7B3444C-D1C9-441D-890D-05E22135DC81Q35198895-DC9DEF19-61FE-4CD4-87E4-7C98C6D825CDQ36150794-67B10026-13A2-4581-A286-72D40ADBEB1BQ36626251-980445A7-01D7-4EC2-8A78-8483A1B68D1FQ36836740-4B6F1D9D-0640-4FB0-AF1A-1872C72CA54DQ37227479-A061A77F-5D2A-427C-B1E1-55AA6D98A3D0Q37352336-7B586585-5989-469D-9B76-0BF210FF19EDQ38677949-5B8A6C6D-C483-43E4-9791-1134A8DD2B34Q38809849-3911CC52-2091-4FB4-81E4-3D24F9E5AF06Q41529086-B509B0A1-C404-4B86-9D67-34B335FE953CQ43789375-AD3778A7-CEA8-41DC-9229-E0FE68359FC6Q46142676-326E17FB-5B94-4AF7-A1AD-5D7FA44AF411Q46357890-B167D3E5-D22B-4FE7-A4FB-6BF28D54CBDBQ48381074-B925D676-7089-4481-8C15-2F41B45CBDDDQ51327838-9D2CDFA6-7863-4F0A-85BA-87CC8B63D6DEQ51487515-A219190B-4AC6-4153-87CB-4B6F411CA345Q51968316-2A309F12-8596-4C8C-A610-7FCFC02916A5
P2860
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@ast
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@en
type
label
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@ast
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@en
prefLabel
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@ast
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@en
P2093
P1476
Amisulpride vs. risperidone in ...... a 6-month double-blind study.
@en
P2093
Amisulpride Study Group
Daniel Sechter
Odile Fleurot
Werner Rein
Yves Lecrubier
P304
P356
10.1016/S0893-133X(02)00375-5
P407
P577
2002-12-01T00:00:00Z
P6179
1031631448